News coverage about Bioptix (NASDAQ:RIOT) has trended somewhat positive on Saturday, according to Accern Sentiment. The research firm identifies positive and negative news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Bioptix earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave media headlines about the technology company an impact score of 44.861442551307 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the news stories that may have effected Accern Sentiment’s scoring:

Shares of Bioptix (NASDAQ:RIOT) traded up $1.50 on Friday, hitting $15.00. 6,030,000 shares of the stock were exchanged, compared to its average volume of 3,570,000. Bioptix has a 1-year low of $3.02 and a 1-year high of $24.00.

Bioptix (NASDAQ:RIOT) last announced its quarterly earnings results on Monday, November 13th. The technology company reported ($0.99) earnings per share (EPS) for the quarter. Bioptix had a negative net margin of 11,828.57% and a negative return on equity of 82.70%.

TRADEMARK VIOLATION NOTICE: This news story was first reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at

Bioptix Company Profile

Riot Blockchain Inc, formerly Bioptix, Inc, intends to gain exposure to the block chain ecosystem through targeted investments in the sector, with a primary focus on the bitcoin and Ethereum blockchains. The Company also provides Enhanced Surface Plasmon Resonance (SPR) platform for the detection of molecular interactions.

Receive News & Ratings for Bioptix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioptix Inc. and related companies with's FREE daily email newsletter.